{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:02:23Z","timestamp":1781661743358,"version":"3.54.5"},"reference-count":16,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Risk-reducing mastectomy is one option for women with hereditary breast and ovarian cancer to reduce the risk of breast cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We analyzed data of the Japanese Organization of Hereditary Breast and Ovarian Cancer on women who were diagnosed as hereditary breast and ovarian cancer by BRCA germline genetic testing between 2010 and 2019 to reveal the rate and likelihood of risk-reducing mastectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 412 women with BRCA1, 271 with BRCA2 and 4 with both female pathogenic variants. Ninety (13.1%) received risk-reducing mastectomy. The rates of risk-reducing mastectomy were statistically significantly higher in women with BRCA1 pathogenic variants than BRCA2, in women who had breast cancer than those who did not, in women with a breast cancer family history than in those without, in mothers than in those without children, in women who were receiving surveillance with MRI than those who were not and in women who received risk-reducing salpingo-oophorectomy than in those who did not on univariate analyses. The ages when they received the genetic testing were statistically significantly younger in the women receiving risk-reducing mastectomy than those who did not receive it. The women with BRCA1 pathogenic variants, personal history of breast cancer, mothers, those receiving MRI surveillance and younger women were independently significantly more likely to receive risk-reducing mastectomy based on multivariate analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The rate of risk-reducing mastectomy was not high in Japan; however, risk-reducing surgery was approved by the Japanese National Medical Insurance for hereditary breast and ovarian cancer patients with breast and\/or ovarian cancer in 2020, so this rate will increase.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jjco\/hyac120","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T20:09:41Z","timestamp":1659125381000},"source":"Crossref","is-referenced-by-count":4,"title":["Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC"],"prefix":"10.1093","author":[{"given":"Shozo","family":"Ohsumi","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, NHO Shikoku Cancer Center , Matsuyama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Breast Surgical Oncology , Department of Surgery, , Tokyo , Japan"},{"name":"School of Medicine, Showa University , Department of Surgery, , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management , School of Medicine, , Tokyo , Japan"},{"name":"Keio University , School of Medicine, , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Watanabe","sequence":"additional","affiliation":[{"name":"School of Nursing and Rehabilitation Sciences, Showa University , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Den","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Public Health, and Preventative Medicine, School of Medicine , , Tokyo , Japan"},{"name":"Showa University , , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Juntendo University, Graduate School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"2022072920093530800_ref1","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1038\/s41467-018-06581-8","article-title":"Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls","volume":"9","author":"Momozawa","year":"2018","journal-title":"Nat Commun"},{"key":"2022072920093530800_ref2","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"2022072920093530800_ref3","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022072920093530800_ref4","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022072920093530800_ref5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers","volume":"177","author":"Heemskerk-Gerritsen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2022072920093530800_ref6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","article-title":"Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer","volume":"140","author":"Evans","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2022072920093530800_ref7","doi-asserted-by":"crossref","first-page":"g226","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"key":"2022072920093530800_ref8","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","volume":"136","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"Int J Cancer"},{"key":"2022072920093530800_ref9","volume-title":"Breast cancer statistics","author":"Breast Cancer Statistics"},{"key":"2022072920093530800_ref10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/GIM.0b013e3181d38f2f","article-title":"Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2","volume":"12","author":"Petrucelli","year":"2010","journal-title":"Genet Med"},{"key":"2022072920093530800_ref11","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. Version 1. 2022 \u2013 August 11, 2021","journal-title":"NCCN Clinical Practice Guidelines in Oncology"},{"key":"2022072920093530800_ref12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRAC2 mutation carriers: the PROSE study group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022072920093530800_ref13","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/annonc\/mdt134","article-title":"Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis","volume":"24","author":"Heemskerk-Gerritsen","year":"2013","journal-title":"Ann Oncol"},{"key":"2022072920093530800_ref14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","article-title":"Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers","volume":"148","author":"Chai","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2022072920093530800_ref15","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","article-title":"Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent","volume":"18","author":"Evans","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022072920093530800_ref16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.maturitas.2013.10.017","article-title":"Risk-reducing mastectomy in BRCA1\/2 mutation carriers: factors influencing uptake and timing","volume":"77","author":"Driel","year":"2014","journal-title":"Maturitas"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyac120\/45191352\/hyac120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyac120\/45191352\/hyac120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T04:08:12Z","timestamp":1700885292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyac120\/6651997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac120","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"article-number":"hyac120"}}